Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer

Abstract Background Immune checkpoint inhibitors (ICIs) are an important therapeutic pillar in metastatic urothelial carcinoma (mUC). The occurrence of immune-related adverse events (irAEs) appears to be associated with improved outcomes in observational studies. However, these associations are like...

Full description

Saved in:
Bibliographic Details
Main Authors: Renate Pichler, Josef Fritz, Sarah Maier, Melanie R. Hassler, Johanna Krauter, David D`Andrea, Ekaterina Laukhtina, Kilian Gust, Keiichiro Mori, Karl H. Tully, Dora Niedersuess-Beke, Lea Korber, Jasmin Alija Spiegelberg, Thomas Bauernhofer, José D. Subiela, Roman Mayr, Andreas Kronbichler, Marco Moschini, Jeremy Teoh, Benjamin Pradere, Shahrokh F. Shariat, Hanno Ulmer, Laura S. Mertens, European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group
Format: Article
Language:English
Published: Springer 2024-12-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Urothelial cancer
Metastatic
Immunotherapy
Immune checkpoint inhibitors
Adverse events
Target trial emulation
Online Access:https://doi.org/10.1007/s00262-024-03871-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03871-7

Similar Items